PRP and exosome hair treatment: questions to ask

PRP and exosome hair treatments require different questions because the evidence, material used and regulatory route may differ. For PRP, ask about diagnosis, blood preparation and trial evidence. For exosomes, first establish product identity, route, legal basis and human evidence. Neither pathway replaces a scalp diagnosis.

Start with the hair-loss diagnosis, not the treatment label

PRP and exosome treatment are often presented as two versions of regenerative hair care. That framing can cause a basic error: choosing an intervention before establishing what is causing the shedding or thinning. Pattern hair loss, telogen effluvium, alopecia areata, traction-related loss, inflammatory scalp disease and scarring alopecia can look similar in an online photograph while requiring very different management. A treatment pathway should therefore begin with a history, scalp examination and, where indicated, further assessment rather than with a package description.

The first question for either pathway is: what is the working diagnosis, and what findings support it? Ask whether the clinician has considered duration, pattern, scalp symptoms, medicines, recent illness, nutritional factors, hormonal context and family history. A diagnosis may be provisional, but it should still be stated. If a practitioner cannot explain whether follicles appear viable, whether inflammation is suspected, or why an alternative diagnosis is less likely, the proposed treatment cannot yet be judged sensibly.

PRP means a preparation made from a person’s own blood. Exosome treatment generally refers to a cell-free preparation used on or in the scalp, but the label alone does not establish what the preparation is, how it is intended to be used or what evidence applies to it. The important distinction is not a claim that one is universally superior. It is that the questions needed to evaluate them are not interchangeable.

The Hampton Clinic offers PRP hair restoration in Bristol. That fact does not answer the clinical questions above. A reader should seek the same diagnostic explanation wherever they consult.

This rule is deliberately conservative. Hair procedures can take time, money and attention away from conditions where delay matters, particularly when there is rapid loss, pain, scaling, pustules or loss of eyebrow hair.

What the evidence table can and cannot tell you

The useful comparison is not whether a website calls either approach advanced. It is the strongest study design available for the particular hair condition, followed by how closely that research resembles the proposed treatment. Randomised controlled trials reduce some sources of bias, but they still vary in diagnosis, preparation methods, injection schedules, outcome measures and follow-up. A case series can describe an experience but cannot reliably show that the intervention caused the result.

For PRP in androgenetic alopecia, systematic reviews of randomised controlled trials exist, although the underlying trials are heterogeneous. That supports a more developed evidence conversation than an individual before-and-after image. It does not create a standard protocol or guarantee a meaningful individual outcome. For exosome preparations in hair loss, published human work has largely been early-stage and non-randomised. Product differences are especially important, so findings from one preparation should not be treated as proof for another.

The regulatory column below is intentionally narrow. It records whether this comparison can rely on a specific UK regulator statement for that indication. A lack of an indication-specific statement is not permission, and it is not a finding that a treatment is unlawful. It means a provider should be able to explain the route and basis they rely on for the exact product and delivery method.

Per-indication evidence and regulator-position table

A patient-facing claim should match this table. If it promises regrowth, presents a case series as a trial, or uses a result from one diagnosis to sell treatment for another, request the underlying evidence and its relevance.

Questions that are specific to PRP hair restoration

PRP has a relatively straightforward starting point because it uses the patient’s own blood, but that does not make every PRP treatment equivalent. The preparation can differ between systems and clinics, including the blood volume taken, the concentration process, whether red or white blood cells are present, whether an activating step is used and how the material is introduced to the scalp. These variables help explain why study findings cannot simply be converted into a promised result.

Ask: what exact preparation will be used, and how does it relate to the studies being cited? A useful answer identifies the preparation process, not merely the acronym. It should also distinguish research evidence from the provider’s own observations. Ask whether treatment is injected, applied after another procedure, or both, since route changes the experience and may change the relevance of cited studies.

Ask about suitability on the day. Because blood is drawn and processed, relevant issues may include a history of fainting with venepuncture, bleeding or clotting problems, current medicines that affect bleeding, active infection and anaemia or other conditions that could affect the blood draw. A clinician should decide relevance in the individual case rather than rely on a generic online exclusion list.

• What diagnosis is being treated, and how will change be measured?
• What does the preparation contain, and how is it produced during the appointment?
• Which published studies use a comparable diagnosis, route and schedule?
• What short-term effects are expected after scalp injections, and what symptoms require contact?
• What happens if photographs and clinical assessment show no meaningful benefit?

Also ask whether established medical options have been discussed where appropriate. A procedural offer should not imply that PRP is the only route, or that it has displaced diagnostic and medical care.

Questions that are specific to exosome treatment

For an exosome proposal, the initial task is to move from a broad label to a precise description. Ask for the product’s full name, intended use, route of administration, batch identification and instructions for use. If the response remains at the level of “stem-cell-derived” or “regenerative”, there is not enough information to compare it with published work or to give informed consent. A biological label does not establish quality, safety or effectiveness for hair loss.

The next question is: what human evidence exists for this exact product, used by this route, for this diagnosis? Evidence about topical use does not automatically apply to scalp injection. Evidence about skin appearance does not automatically apply to androgenetic alopecia. Evidence from laboratory work or animals is not evidence of clinical benefit in people. A provider should be able to separate these categories without treating them as interchangeable.

Ask who is responsible for the product’s regulatory assessment and which UK framework they say applies. The Medicines and Healthcare products Regulatory Agency regulates medicines and medical devices within its remit, but legal classification depends on the product and the claims, presentation and use. Do not accept a general statement that a product is “regulated” as a substitute for an explanation of the precise route being used. Written confirmation may be appropriate where an injection is proposed.

Questions about traceability are also central. Ask what records will identify the batch, how adverse events are handled, whether there is a recall process and what information will be supplied for your own records. These are governance questions, not technical curiosities. They matter most where the evidence base is early and the product category is described broadly.

If the provider cannot identify the product, route, evidence and regulatory rationale in writing, do not treat the uncertainty as a minor administrative gap.

This is not a verdict on every exosome-related proposal. It is a threshold for a decision that involves an intervention rather than a cosmetic claim.

Compare routes, outcomes and consent rather than promises

Once diagnosis and evidence have been discussed, compare the two pathways through practical questions that are answerable before treatment. First, define the outcome. Is the aim reduced shedding, improved photographic density, stabilisation, a change in hair calibre, or a subjective improvement in styling? These are different outcomes. A consent discussion should say which is being measured, how it will be measured and at what interval. Standardised photographs can be useful only if lighting, angle, hair length and parting are reasonably consistent.

Second, ask what the course involves without treating the number of sessions as proof that it works. The clinician should explain why the proposed timing and review point are chosen, whether that schedule reflects evidence or local practice, and what would count as a reason to stop. A course that has no pre-agreed reassessment point can make it difficult to recognise lack of benefit.

Third, ask about adverse effects in route-specific terms. Scalp injection can involve discomfort, bruising, swelling, bleeding and infection risk. Topical application has different practical considerations. The person obtaining consent should explain known risks, material uncertainties and the action to take if symptoms occur. A generic consent form does not replace this conversation.

Comparisons with polynucleotide treatment or radiofrequency microneedling should remain equally route- and indication-specific. They are not substitutes simply because they may appear in the same aesthetic consultation.

When declining or delaying is the safer decision

A decision to decline is appropriate when the information needed for consent is missing, not only when a treatment is known to be unsuitable. This matters for exosome treatment in particular, where a broad treatment name can conceal differences in product, route and claimed purpose. It also applies to PRP when the consultation has skipped diagnosis or converted limited evidence into a certainty.

Delay the decision if the hair loss is rapid, patchy, painful, inflamed or accompanied by scaling, pustules or scarring changes. Those features may warrant medical assessment before a cosmetic procedure. Delay also makes sense where there is pregnancy, breastfeeding, a significant medical condition, medicines affecting bleeding or immunity, or a recent change in health that has not been discussed with an appropriate clinician. The point is not that every such circumstance rules treatment out. It is that individual suitability cannot be decided from a marketing questionnaire.

Use the refusal criteria below as a practical screen.

1. The provider cannot state the working hair-loss diagnosis.
2. The proposed outcome is a guarantee or is too vague to measure.
3. Before-and-after images are offered in place of relevant studies.
4. For PRP, the preparation and route are not explained.
5. For exosomes, the exact product and route are not identified.
6. Evidence from another condition, route or product is presented as direct proof.
7. The regulatory explanation consists only of the word “approved” or “regulated”.
8. There is no written plan for follow-up, adverse events or stopping.
9. You are discouraged from considering medical assessment or alternatives.

These criteria do not require a patient to become a regulator or researcher. They identify when the provider has not supplied the minimum information needed to weigh uncertainty. Waiting for clearer information is a valid outcome of a consultation.

Limits of this comparison

This reference compares the questions that should be asked when PRP and exosome treatment are proposed for hair loss. It does not diagnose hair conditions, determine individual eligibility, interpret blood tests, or give legal advice about a particular product. It also does not decide whether a given provider is compliant with professional, premises, advertising or product rules. Those matters depend on facts that may change, including the exact material, claims, route and setting.

The evidence table is deliberately indication-specific. It should not be used to infer effectiveness for beard growth, eyebrows, post-transplant healing, scalp symptoms or non-hair uses. Nor should a finding in androgenetic alopecia be assumed to apply to alopecia areata, scarring alopecia or acute shedding. These conditions have different causes and may need different forms of assessment.

Regulatory information also requires current checking. The MHRA’s remit is relevant to medicines and medical devices, but a broad treatment term is not itself a legal classification. Ask the proposing clinician to provide the regulatory rationale that applies at the time, in writing where appropriate. Advertising language, professional standards and premises regulation can involve other bodies and rules beyond the scope of this page.

Finally, this comparison does not cover costs, rankings of providers or claims of superiority. The decision rule is simpler: choose neither pathway until the diagnosis, evidence, product or preparation, route, risks, alternatives and review plan can be understood well enough to make a voluntary decision.

Disclosure. This article names a business whose website is managed by the same group as this publication, which is a commercial relationship. The business did not write or approve the article, and it is named because it is relevant to the subject.